Inovio Pharmaceuticals, Inc. is focused on the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, to prevent or treat cancers and chronic infectious diseases. Inovio has a robust pipeline of preclinical and clinical-stage electroporation-based DNA vaccines. The company intends to develop individual products through to early clinical validation and out-license these products to complete clinical development and commercialization. Inovio also licenses its proprietary electroporation DNA delivery systems for partners and collaborators to use in conjunction with DNA-based immunotherapies. Inovio's list of partners and collaborators includes organizations such as Merck, University of Southampton, and the HIV Vaccine Trials Initiative. The company conducts business through wholly-owned subsidiaries, Genetronics, Inc. and VGX Pharmaceuticals, LLC.

Acquired Companies: VGX Pharmaceuticals